The study is testing tocilizumab, a medicine for rheumatoid arthritis and COVID-19, to help people with sickle cell disease who have acute chest syndrome (a lung problem). Tocilizumab blocks IL-6 receptors, which are parts of cells affected during sickness. The researchers want to see if this medicine can improve oxygen levels and other health signs in patients.

This is a phase II study, meaning it's still early in testing. Patients will get two treatments: a real tocilizumab dose and a fake one (placebo) at different times without knowing which is which. Researchers will compare results to see if tocilizumab works better than placebo.

• The study is for people 12 years and older with sickle cell disease.
• Participants stay in the hospital for the study and will receive two doses over about two days.
• Certain health conditions and medications may prevent participation, so check with your doctor.

Before joining, it’s important to consider the requirements and talk with a healthcare provider to understand potential benefits and risks.